USNA

Usana Health Sciences

Stock NYSE – Stock Market Prices, News & Analysis

International provider of health and wellness products, including nutritional supplements and skincare products.

$ 16.90
1.86 %

Usana Health Sciences

$ 16.90
1.86 %
USNA

International provider of health and wellness products, including nutritional supplements and skincare products.

Price history of Usana Health Sciences
Price history of Usana Health Sciences

Performance & Momentum

6 Months 35.94 %
1 Year 35.91 %
3 Years 72.99 %
5 Years 82.38 %

Strategic Analysis

Usana Health Sciences • 2026

Usana Health Sciences Inc positions itself as an international player specializing in health and wellness products, with a focus on nutritional supplements and skincare. Its model relies on direct sales, targeting a clientele that values quality and effectiveness in a growing sector related to health prevention and wellness.

Strengths
  • Diversified global presence allowing exposure to multiple high-potential markets.
  • Integrated offering combining nutrition and skincare, creating a differentiating product synergy.
  • Direct selling distribution model promoting customer loyalty and organic growth.
Weaknesses
  • Sustained negative stock performance reflecting difficulties in regaining investor confidence.
  • Sensitivity to strict regulations regarding dietary supplements in several jurisdictions.
Momentum

The current momentum is marked by a persistent negative dynamic impacting the stock's valuation. This trend reflects a heightened competitive landscape and unmet high expectations, necessitating increased strategic vigilance before taking a position.

Analysis performed 3 weeks ago

Similar stocks to Usana Health Sciences

Was this page helpful?

Your feedback helps us improve our research.

Take control
of your investments

Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.

  • Real-time multi-portfolio tracking
  • AI analysis of your positions
  • Counter your cognitive biases
Anantys Invest on iPhone